Blockchain Registration Transaction Record

Soligenix Pioneers Immune-Modulating Therapy to Combat Antibiotic Resistance

Soligenix Inc. advances SGX943, a novel therapy for antibiotic-resistant infections, and develops vaccines for COVID-19 and more, marking a leap in biopharmaceutical innovation.

The development of SGX943 by Soligenix Inc. is a critical advancement in the fight against antibiotic-resistant bacterial infections, a growing global health crisis. This therapy's unique mechanism of enhancing the body's immune response rather than directly attacking bacteria could revolutionize treatment paradigms, offering hope for patients with limited options. Additionally, Soligenix's work on vaccines for COVID-19 and other deadly pathogens underscores its vital role in addressing current and future public health challenges.